The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.

TitleThe extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
Publication TypeJournal Article
Year of Publication2017
AuthorsBegum A, Ewachiw T, Jung C, Huang A, K Norberg J, Marchionni L, McMillan R, Penchev V, Rajeshkumar NV, Maitra A, Wood L, Wang C, Wolfgang C, DeJesus-Acosta A, Laheru D, Shapiro IM, Padval M, Pachter JA, Weaver DT, Rasheed ZA, Matsui W
JournalPLoS One
Volume12
Issue7
Paginatione0180181
Date Published2017
ISSN1932-6203
KeywordsAldehyde Dehydrogenase, Animals, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Cell Movement, Cell Proliferation, Cell Self Renewal, Clone Cells, Collagen Type I, Extracellular Matrix, Focal Adhesion Protein-Tyrosine Kinases, Humans, Integrin beta1, Mice, Nude, Neoplasm Metastasis, Neoplastic Stem Cells, Pancreatic Neoplasms, Protein Kinase Inhibitors, Signal Transduction
Abstract

Cancer stem cells (CSCs) play an important role in the clonogenic growth and metastasis of pancreatic ductal adenocarcinoma (PDAC). A hallmark of PDAC is the desmoplastic reaction, but the impact of the tumor microenvironment (TME) on CSCs is unknown. In order to better understand the mechanisms, we examined the impact of extracellular matrix (ECM) proteins on PDAC CSCs. We quantified the effect of ECM proteins, β1-integrin, and focal adhesion kinase (FAK) on clonogenic PDAC growth and migration in vitro and tumor initiation, growth, and metastasis in vivo in nude mice using shRNA and overexpression constructs as well as small molecule FAK inhibitors. Type I collagen increased PDAC tumor initiating potential, self-renewal, and the frequency of CSCs through the activation of FAK. FAK overexpression increased tumor initiation, whereas a dominant negative FAK mutant or FAK kinase inhibitors reduced clonogenic PDAC growth in vitro and in vivo. Moreover, the FAK inhibitor VS-4718 extended the anti-tumor response to gemcitabine and nab-paclitaxel in patient-derived PDAC xenografts, and the loss of FAK expression limited metastatic dissemination of orthotopic xenografts. Type I collagen enhances PDAC CSCs, and both kinase-dependent and independent activities of FAK impact PDAC tumor initiation, self-renewal, and metastasis. The anti-tumor impact of FAK inhibitors in combination with standard chemotherapy support the clinical testing of this combination.

DOI10.1371/journal.pone.0180181
Alternate JournalPLoS One
PubMed ID28692661
PubMed Central IDPMC5503247
Grant ListK24 CA198315 / CA / NCI NIH HHS / United States
R01 CA150142 / CA / NCI NIH HHS / United States
R01 CA193887 / CA / NCI NIH HHS / United States
T32 GM007309 / GM / NIGMS NIH HHS / United States
Related Faculty: 
Luigi Marchionni, M.D., Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700